EED-226 is a novel allosteric Polycomb repressive complex 2 (PRC2) inhibitor (IC50 = 23.4 nM when the substrate is H3K27me0 peptide and IC50 = 53.5 nM when the substrate is mononucleosom). EED-226 induces a conformational change via binding EED which invalidates PRC2 activity. PRC2 plays pivotal roles in transcriptional regulation. EED-226 has the potential to treat PRC2-dependent cancers, such as human lymphoma xenograft tumors.
Products > Drug Discovery > Inhibitor > Other Inhibitors | Products > Drug Discovery > Inhibitor
感谢您来到爆牛贸易,请为我们留言或者使用以下方式联系我们,我们将尽快给您回复,并为您提供最真诚的服务,谢谢。